REG - Futura Medical PLC - Notice of AGM and availability of Annual Report

Futura MedicalAnnouncement

26/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230526:nRSZ6995Aa&default-theme=true

RNS Number : 6995A  Futura Medical PLC  26 May 2023

 

  26 May 2023

 

  Futura Medical plc

("Futura" or the "Company")

Notice of AGM and availability of Annual Report

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, today
announces its Annual General Meeting ("AGM") will be held at 10:00am on
Thursday 22 June 2023 at the offices of Liberum Capital Limited, Ropemaker
Place, 25 Ropemaker Street, London EC2Y 9LY.

 

If you wish to attend the meeting in person, please register your interest,
prior to 10:00am on Monday 19 June 2023, at
investor.relations@futuramedical.com.

 

Shareholders are asked to cast their vote as follows: (1) casting your proxy
vote online by logging on to www.signalshares.com
(https://www.signalshares.com/) and following the instructions; or (2) in the
case of CREST members, by utilising the CREST electronic proxy appointment
service; or (3) requesting a hard copy form of proxy directly from the
registrars, Link Group. If you choose to attend the Annual General Meeting in
person instead of appointing the Chairman of the meeting as proxy, as we
strongly recommend, you will still be able to vote in person at the Annual
General Meeting.

 

If you are not attending the Annual General Meeting in person, your proxy vote
will need to be logged by 10:00am on Tuesday 20 June 2023 as no online voting
will take place in-real time during the meeting itself.

 

The Company will operate an audio dial-in facility only to allow shareholders
to listen to the business of the meeting: shareholders will need to be
confirmed as a shareholder or present a letter of representation before
details of how to access this facility are released to them via email the
morning of the meeting. You can request access by emailing:
investor.relations@futuramedical.com prior to 10:00am on Monday 19 June 2023.

 

This document should be read in conjunction with the Futura Medical plc annual
report and accounts. If you are in any doubt as to the action you should take,
you are recommended to seek your own personal financial advice immediately
from your stockbroker, bank manager, solicitor, accountant, or independent
advisor, who, if you are taking advice in the United Kingdom, is authorised
pursuant to the Financial Services and Markets Act 2000.

 

Shareholders will not get an opportunity to vote or ask questions or
participate in any other way during the call.

 

Annual Report

Futura's annual report and accounts for the year ended 31 December 2022 (the
"Annual Report") is available to shareholders as an electronic communication
pursuant to the Companies Act 2006 and is now available on the Company's
website www.futuramedical.com
(https://www.futuramedical.com/investor-centre/corporate-documentation/) ,
along with the Notice of AGM.

 

-ENDS-

 

For further information, please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted an initial Phase 3 study using MED3000 in ED,
referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A
second confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED patients and
endpoints at 24 weeks, demonstrating that MED3000 presents an effective
clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for an 'Over the
Counter' classification.

 

Eroxon® is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile dysfunction
under the brand Eroxon® with a key claim of "Helps you get an erection within
10 minutes". Eroxon® is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by the Company
and also in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved. www.eroxon.com
(http://www.eroxon.com)

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSBXGDUCXDDGXU